Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Stock Hits Forecast Price Target with 18.52% Profit on QuantWave Platform

May 03, 2023

On January 3, 2023, QuantWave, the automated forecasting platform, issued a signal for ELI LILLY AND COMPANY (LLY) stock to go long when it was trading at 357.73 $. This forecast has proven to be highly accurate as the stock reached the target price of 423.98 $ on May 3, 2023, delivering a profit of 18.52% to investors who followed the prediction.

The achievement of the price target for LLY stock showcases the effectiveness of QuantWave's analytics in predicting market movements. The platform utilizes advanced algorithms and data analysis to provide users with reliable forecasts for a wide range of stocks, enabling them to capitalize on potential profit opportunities.

Several factors may have contributed to the successful forecast for LLY stock. Positive developments in the pharmaceutical industry, strong financial performance by ELI LILLY AND COMPANY, and overall market trends could have played a role in driving the stock price higher and meeting the forecasted target.

QuantWave's accurate prediction for LLY stock underscores the platform's ability to help investors make informed decisions and achieve profitable outcomes in the stock market. Users can leverage QuantWave's forecasts to navigate the complex world of investing and maximize their returns.

For those interested in delving deeper into QuantWave's investment strategy, QuantSchool offers a comprehensive professional investment framework. QuantSchool provides key principles for generating consistent income using the QuantWave forecasting system, empowering users to enhance their investment knowledge and skills.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYJuly 20, 2025Strong Q2 Forecast for ELI LILLY AND COMPANY by J.P. Morgan  ~1 min.

According to J.P. Morgan, Eli Lilly and Company is expected to have a strong second quarter performance. The pharmaceutical giant has been receiving positive attention from investors and analysts alike....

LLYMarch 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation  ~2 min.

Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....

LLYMarch 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results  ~2 min.

Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....

LLYMarch 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry  ~1 min.

Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....

LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....

LLYMarch 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry?  ~2 min.

Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....

LLYMarch 14, 2025Eli Lilly and Company Reports Promising Results in Hair Regrowth Study  ~1 min.

Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....

LLYFebruary 28, 2025Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding 50 billion  ~1 min.

Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....

LLYFebruary 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development  ~1 min.

Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....

LLYFebruary 26, 2025ELI LILLY AND COMPANY Launches Additional Zepbound Vial Doses and Offers New Savings  ~2 min.

ELI LILLY AND COMPANY has recently announced the launch of additional Zepbound vial doses, as well as new savings for self-pay patients....

REGNApril 8, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target with 20% Profit: QuantWave Analysis  ~1 min.

In a recent success for QuantWave's forecasting platform, the stock of REGENERON PHARMACEUTICALS, INC. has hit its price target with a 20% profit margin....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Hits QuantWave Forecast Target with 7.59% Profit  ~2 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) has successfully reached the forecast price target set by QuantWave on June 30, 2025....

LLYAugust 14, 2023ELI LILLY AND COMPANY Hits Price Target Forecast with 20.96% Profit  ~2 min.

ELI LILLY AND COMPANY (LLY) recently achieved the price target forecast set by QuantWave on June 13, 2023. The stock was signaled for a long position at a price of 439.41 $....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Stock Hits Forecasted Price Target with 8.64% Profit  ~1 min.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX) stock successfully reached the forecasted price target set by QuantWave on 2025-06-20, with a predicted long direction. The stock was valued at 440....

VRTXJuly 9, 2025VERTEX PHARMACEUTICALS INCORPORATED Stock Reaches Price Target Forecast with 8.02% Profit  ~1 min.

VERTEX PHARMACEUTICALS INCORPORATED stock successfully reached the price target forecast set by QuantWave on July 9, 2025....